AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21415398
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injection(s) plus a 4‐week therapy program
Trial: 21415398
Drug: Therapy program
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy program alone
Trial: 18075401
Drug: 1-g EMLA
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-g EMLA cream applied 1 hour before the procedure
Trial: 18075401
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied 1 hour before the procedure
Trial: 18075401
Drug: 1-g EMLA
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-g EMLA cream
Trial: 14746532
Drug: Rituximab in
RxNorm normalized name: rituximab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab in combination with standard chemotherapy
Trial: 11683282
Drug: Subcutaneous curettage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous curettage
Trial: 11683282
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of botulinum toxin A (BT-A)
Trial: 26124084
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy (75mg/m2 docetaxel d1, 75mg/m2 cisplatin d1, and 750mg/m2/day 5‐fluorouracil d1‐5) followed by radical surgery and post‐operative radiotherapy
Trial: 22025880
Drug: Probiotic goat
RxNorm normalized name: Goat milk
DrugBank: Goat milk (DB10542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic goat yogurt with 10(9) CFU/mL Bifidobacterium longum
Trial: 18481713
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (oral administration according to WHO Three Step Administration Principle: aspirin for mild pain, codeine for moderate pain, morphine for severe pain)
Trial: 14579873
Drug: Control manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control manual toothbrush (Oral-B Cross Action)
Trial: 1953532
Drug: Oral vaccine
RxNorm normalized name: RotaTeq Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vaccine containing killed Haemophilus influenzae
Trial: 7447203
Drug: Low-dose verapamil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose verapamil (0.075 mg/kg body weight)
Trial: 7447203
Drug: High-dose verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose verapamil (0.15 mg/kg body weight)
Trial: 30448451
Drug: Insulin degludec/insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin degludec/insulin aspart (IDegAsp) once-daily (OD)
Trial: 30448451
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (IGlar) U100 + insulin aspart (IAsp) once-daily (OD)
Trial: 26896686
Drug: Cervarix™ HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervarix™ HPV vaccine
Trial: 26896686
Drug: Gardasil™ HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gardasil™ HPV vaccine
Trial: 20308489
Drug: Body Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body Weight (BW) group with contrast dose of 360 mg I/kg BW
Trial: 20308489
Drug: Body Surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body Surface Area (BSA) group with contrast dose of 12,753 mg I/m(2) BSA
Trial: 17369673
Drug: Surgery as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery as the dominant form of therapy
Trial: 12395978
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg alone
Trial: 12395978
Drug: Concomitant nateglinide
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant nateglinide 120 mg and diclofenac 75 mg
Trial: 10048900
Drug: Low-dose nandrolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nandrolone decanoate (65 mg/week)
Trial: 10048900
Drug: High-dose nandrolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nandrolone decanoate (200 mg/week)
Trial: 10048900
Drug: Nandrolone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nandrolone treatment (both doses)
Trial: 10048900
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate therapy (12-week open-label follow-up)
Trial: 31599827
Drug: Self-discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-discontinuation
Trial: 31599827
Drug: Office discontinuation
RxNorm normalized name: Entex HC Discontinued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office discontinuation
Trial: 27338456
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 400 μg (two times/daily) for three months
Trial: 22493925
Drug: Tuina treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuina treatment (local manipulations on breasts combined with acupoint manipulations)
Trial: 18202422
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (100 mg/m²) with carboplatin (AUC = 6 mg/mL x min)
Trial: 18202422
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of paclitaxel (225 mg/m²) and carboplatin (AUC = 6) every 3 weeks
Trial: 24456145
Drug: IOP-lowering therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IOP-lowering therapy
Trial: 15700191
Drug: No IOP-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IOP-lowering therapy
Trial: 10626564
Drug: Oestrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen therapy initiated at 12 years of age
Trial: 10626564
Drug: Oestrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen therapy initiated at 15 years of age
Trial: 8529507
Drug: Glimepiride (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (in severe patients treated by large doses of glibenclamide)
Trial: 1949925
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg i.v.
Trial: 31026534
Drug: Levodopa therapy
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa therapy (ON-medication condition)
Trial: 31026534
Drug: Levodopa therapy
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa therapy (OFF-medication condition)
Trial: 26220734
Drug: Soluble tumor
RxNorm normalized name: SOLUBLE TUMOR NECROSIS FACTOR (1-METHIONINE,31-CYSTEINE,69-VALINE,87-HISTIDINE,101-ALANINE,145-ARGININE) (HUMAN CONSTRUCT XPRO1595), 31-THIOETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL)-.OMEGA.-METHOXYPOLY(OXY-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble tumor necrosis factor receptor‐2 (sTNFRII)
Trial: 19671303
Drug: TENS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS treatment at acupoints ST36 (Zusanli) and PC6 (Neiguan) twice a day for 2 weeks
Trial: 15777070
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 1200 IU daily
Trial: 9581727
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (2 g three times daily)
Trial: 7994817
Drug: Renin inhibitor
RxNorm normalized name: Renin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin inhibitor remikiren
Trial: 7994817
Drug: Converting enzyme
RxNorm normalized name: Prohormone converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting enzyme inhibitor enalaprilat
Trial: 7994817
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of remikiren and enalaprilat
Trial: 2662790
Drug: Repeat trial
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat trial of conservative therapy
Trial: 30875343
Drug: ECT plus
RxNorm normalized name: Protect Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECT plus 5 mg/d donepezil
Trial: 29169373
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of hypertensive medication
Trial: 29169373
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of hypertensive medication
Trial: 26427805
Drug: Accelerated fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated fractionation (AF) - 1.1Gy+2Gy per day, 5 days/week for 4.5 weeks, total dose 68Gy
Trial: 26427805
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation (CF) - 2Gy per day, 5 days/week for 7 weeks, total dose 68Gy
Trial: 18422441
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g valacyclovir TID for 7 days
Trial: 18422441
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g valacyclovir TID for 7 days
Trial: 18422441
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg acyclovir 5 times per day for 7 days (previous study)
Trial: 12846625
Drug: Neuromuscular-blocking agent
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular-blocking agent (NMB) with tracheal tube ventilation
Trial: 7798068
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg
Trial: 26418414
Drug: CAPSULE (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPSULE (50 mg)
Trial: 26418414
Drug: TABLET (diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TABLET (diclofenac sodium enteric-coated tablet)
Trial: 24831596
Drug: Traditional endovascular
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional endovascular coiling therapy
Trial: 22221615
Drug: PAB-F (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAB-F (pantoprazole 40mg-bid, amoxicillin 1g-bid, bismuth subcitrate 240mg-bid for 2 weeks, furazolidone 200mg-bid for the first week)
Trial: 22221615
Drug: PA-CT (pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-CT (pantoprazole 40mg-bid for 10 days, amoxicillin 1g-bid for the first 5 days, clarithromycin 500mg-bid plus tinidazole 500mg-bid for the second 5 days)
Trial: 20460065
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (RSWT)
Trial: 9358111
Drug: Topical oat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical oat colloidal grain suspension (0.007% and 0.7%)
Trial: 9358111
Drug: Topical rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical rice colloidal grain suspension (0.007% and 0.7%)
Trial: 8261678
Drug: Intravenous calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous calcitriol (2 micrograms postdialysis three times per week)
Trial: 8261678
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (2 micrograms postdialysis three times per week)
Trial: 8261678
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and oral calcitriol
Trial: 29967954
Drug: Prasugrel (20/3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (20/3.75 mg, loading/maintenance dose) with aspirin (100 mg)
Trial: 29967954
Drug: Clopidogrel (300/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300/75 mg) with aspirin (100 mg)
Trial: 27562352
Drug: Tea catechin
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tea catechin beverage (570 mg)
Trial: 20182703
Drug: tamsulosin, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin, 0.4 mg/day for 4 weeks
Trial: 12357146
Drug: Goal-directed intraoperative
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed intraoperative fluid administration (protocol group)
Trial: 16351767
Drug: Olive oil-based
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil-based intravenous lipid emulsion (ILE)
Trial: 1912556
Drug: Self-administered IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 1 year (n = 10)
Trial: 1912556
Drug: Self-administered IFN
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered IFN alpha‐2b, 3 million units subcutaneously thrice weekly for 6 months (n = 6 after initial no-treatment)
Trial: 1912556
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) (n = 8)
Trial: 1912556
Drug: IFN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN treatment for 1 year
Trial: 1912556
Drug: IFN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN treatment for 6 months
Trial: 31050709
Drug: AKT-inhibitors in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKT-inhibitors in combination with first-line chemotherapy
Trial: 28425253
Drug: B2-G haplotype
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B2-G haplotype
Trial: 26019464
Drug: Bio‐Three tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio‐Three tablets (9 tablets/day) containing 2 mg of lactomin, 10 mg of Clostridium butyricum TO‐A, and 10 mg of Bacillus mesentericus TO‐A
Trial: 26019464
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (9 tablets/day)
Trial: 19430040
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antioxidant Phenovin and immunomodulator Una de gato
Trial: 15538131
Drug: S-adenosyl-L-methionine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (800 to 1600 mg)
Trial: 9269759
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered intravenously 2 hours before endotoxin challenge
Trial: 9269759
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF; 5 microg/kg) administered subcutaneously 24 hours before endotoxin challenge
Trial: 8329254
Drug: Buprenorphine 0.15
RxNorm normalized name: buprenorphine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.15 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Trial: 8329254
Drug: Papaveretum 10
RxNorm normalized name: papaveretum 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaveretum 10 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Trial: 8329254
Drug: Buprenorphine 0.15
RxNorm normalized name: buprenorphine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 0.15 mg i.v. followed by papaveretum 20 mg i.m. and then buprenorphine 0.4 mg sublingual
Trial: 8329254
Drug: Papaveretum 10
RxNorm normalized name: papaveretum 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaveretum 10 mg i.v. followed by buprenorphine 0.3 mg i.m. and then buprenorphine 0.4 mg sublingual
Trial: 2883393
Drug: Ty21a attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a attenuated Salmonella typhi oral vaccine in an enteric‐coated formulation
Trial: 2883393
Drug: Ty21a vaccine
RxNorm normalized name: Typhoid Vaccine Live Ty21a
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ty21a vaccine in gelatin capsules with sodium bicarbonate
Trial: 26438518
Drug: Milk powder
RxNorm normalized name: Milk powder
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder supplementation with 300 mg calcium per day (Group A)
Trial: 26438518
Drug: Milk powder
RxNorm normalized name: Milk powder
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder supplementation with 600 mg calcium per day (Group B)
Trial: 26438518
Drug: Milk powder
RxNorm normalized name: Milk powder
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder supplementation with 900 mg calcium per day (Group C)
Trial: 25251201
Drug: Injectable, extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable, extended-release naltrexone
Trial: 23063084
Drug: Cefazolin 1
RxNorm normalized name: cefazolin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 1 g IV (GrAP)
Trial: 23063084
Drug: No antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotic (GrAPn)
Trial: 15530588
Drug: Reduction of
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction of at least 5 g
Trial: 12180276
Drug: Topiramate (50-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (50-300 mg/day)
Trial: 12180276
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (100-400 mg/day)
Trial: 9666536
Drug: Targeted low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Targeted low-dose warfarin (INR 1.5-2.0)
Trial: 8582151
Drug: Active antiplatelet
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antiplatelet regimens (including aspirin)
Trial: 31550951
Drug: Single lightwand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single lightwand (Group L)
Trial: 21787508
Drug: Taper 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper 0.04
Trial: 21787508
Drug: Taper 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper 0.06
Trial: 21787508
Drug: Taper 0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper 0.08
Trial: 9299674
Drug: Decision-making strategy
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decision-making strategy A (combination of disease indices and serum concentrations of orosomucoid)
Trial: 8117512
Drug: Subtrochanteric resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtrochanteric resection and double plate compound osteosynthesis (DPCO)
Trial: 31101513
Drug: Co-treatment with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-treatment with buspirone and AAPDs
Trial: 31101513
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with AAPDs
Trial: 19187641
Drug: Rapid fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid fluid expansion (Group I, n = 36) at a rate of 10-15 ml x kg(‐1) x h(‐1)
Trial: 19187641
Drug: Controlled fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled fluid expansion (Group II, n = 40) at a rate of 5-10 ml x kg(‐1) x h(‐1)
Trial: 17202428
Drug: Real-time feedback
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time feedback display of movement; adaptation to three different rotations of feedback display; sequential adaptation process.
Trial: 11573597
Drug: Erythromycin 1
RxNorm normalized name: erythromycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1 mg kg(‐1)
Trial: 11573597
Drug: Metoclopramide 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.15 mg kg(‐1)